RE:Resistance to ADCs in the treatment of solid tumors Should read: " ... by "priming" the immune system and remodeling the TME in advance of the addition anti-PD-(L)1 antibody treatment, pelareorep is able to synergistically combine with immune checkpoint inhibitors (ICI) ... making ONCY's pelareorep a critical facilitator to any proposed ADC / ICI combination,..."